EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Echocardiographic effects of dupilumab in patients with severe type 2 asthma

Corrado Pelaia, Giuseppe Armentaro, Chiara Lupia, Antonio Giacalone, Gianluca Ippolito, Daniela Pastore, Sofia Miceli, Carlo Alberto Pastura, Giandomenico Severini, Carlo Fuoco, Alberto Panza, Filippo Capilupi und 6 weitere

Pulmonary Pharmacology & Therapeutics · 2026

DOI: 10.1016/j.pupt.2026.102409 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026. Verfasst von Corrado Pelaia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy. Electronic address: pelaia.corrado@unicz.it. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Anti-Asthmatic Agents. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Severe asthma is characterized by impaired lung function and elevated cardiovascular risk. Type 2 inflammation, primarily mediated by IL-4 and IL-13, contributes to both airway and cardiac remodeling. Dupilumab, an IL-4Rα antagonist, has shown efficacy in improving respiratory outcomes; however, its impact on cardiac function remains insufficiently studied. OBJECTIVE: To assess the 12-month effects of dupilumab on echocardiographic parameters and evaluate its potential association with clinical remission in patients with severe type 2 asthma. METHODS: This single-centre observational study enrolled 24 patients with severe type 2 asthma receiving dupilumab. Echocardiographic assessments and lung function tests were conducted at baseline and after 12 months. Clinical remission was defined by meeting all of the following: zero exacerbations, zero OCS use, ACT score ≥20, and pre-bronchodilator FEV1 ≥ 80 % predicted. RESULTS: Twelve-month dupilumab therapy led to significant improvements in both cardiac and respiratory parameters. LV-GLS improved from -17.00 % to -19.00 % and RV-GLS from -17.33 % to -19.11 % (both p < 0.0001). TAPSE and TAPSE/S-PAP ratio also increased significantly (p < 0.0001). Lung function showed notable gains in FEV1 and FEF25-75, alongside reductions in residual volume and airway resistance. Clinical remission was achieved by 45.83 % of patients. Baseline LV-GLS emerged as a strong predictor of remission (AUC = 0.832), unlike RV-GLS (AUC = 0.545). CONCLUSIONS: Dupilumab markedly improved cardiac and pulmonary function and may promote clinical remission. Baseline LV-GLS may serve as a predictive marker, supporting cardiovascular assessment in asthma management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaAnti-Asthmatic AgentsHumansFemaleMaleMiddle AgedEchocardiographySeverity of Illness IndexRespiratory Function TestsAdultRemission Induction

Stichwörter der Autor:innen

Clinical remissionDupilumabEchocardiographyGlobal longitudinal strainSevere asthma

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy. Electronic address: pelaia.corrado@unicz.it.
  • Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
  • Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
  • Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.

Zitieren

APA

Pelaia, C., Armentaro, G., Lupia, C., Giacalone, A., Ippolito, G., Pastore, D., Miceli, S., Pastura, C. A., Severini, G., Fuoco, C., Panza, A., Capilupi, F., Scarcelli, M. R., Piazzetta, G. L., Chiarella, E., Vatrella, A., Pelaia, G., & Sciacqua, A. (2026). Echocardiographic effects of dupilumab in patients with severe type 2 asthma. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2026.102409

Vancouver

Pelaia C, Armentaro G, Lupia C, Giacalone A, Ippolito G, Pastore D, et al. Echocardiographic effects of dupilumab in patients with severe type 2 asthma. Pulmonary Pharmacology & Therapeutics. 2026. doi:10.1016/j.pupt.2026.102409

BibTeX
@article{Pelaia2026,
  author = {Pelaia, Corrado and Armentaro, Giuseppe and Lupia, Chiara and Giacalone, Antonio and Ippolito, Gianluca and Pastore, Daniela and Miceli, Sofia and Pastura, Carlo Alberto and Severini, Giandomenico and Fuoco, Carlo and Panza, Alberto and Capilupi, Filippo and Scarcelli, Maria Rosangela and Piazzetta, Giovanna Lucia and Chiarella, Emanuela and Vatrella, Alessandro and Pelaia, Girolamo and Sciacqua, Angela},
  title = {Echocardiographic effects of dupilumab in patients with severe type 2 asthma},
  journal = {Pulmonary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1016/j.pupt.2026.102409}
}
Kostenlos starten →